EyePoint, Inc. (EYPT) Stock Analysis

Q: What is the EYPT stock price target?

Take-profit $14.88 (+27.2% upside). Target $14.88 (+21.0%), stop $11.33 (−8.6%), A.R:R 0.0:1.

Q: Is EYPT overvalued or undervalued?

EyePoint, Inc. trades at a P/E of N/A (forward -4.1). TrendMatrix value score: 5.0/10. Overall verdict: Hold.

Q: What do analysts say about EYPT?

18 analysts cover EYPT with a consensus score of 4.3/5. Average price target: $37.

Falling Knife setup

HoldVALUE-TRAP 1/5Moderate ConfidenceUpdated 1 days ago (May 19, 2026, 7:46 AM ET)

Healthcare · Biotechnology

$12.30+27.2% A.UpsideScore 5.1/10#94 of 157 Biotechnology

QualityF-score4 / 9FCF yield-17.20%

Stop $11.33Target $14.88(resistance)A.R:R 0.0:1

Analyst target$37.00+200.8%12 analysts

$14.88our TP

$12.30price

$37.00mean

$68

Hold if already holding. Not a fresh buy at $12.30, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $37.00 vs price $11.70 — ratio 3.2×). Rejected, falling back to technical TP.; Market cap $0.98B below $1B minimum. Chart setup: Death cross, below all MAs, RSI 32, MACD bearish. Market cap $0.98B below $1B minimum. Not in investable universe. Score 5.1/10, moderate confidence.

Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.

Recent Developments — EyePoint, Inc.

Latest news

RBC Capital Maintains Outperform on EyePoint, Lowers Price Target to $37 — benzinga May 7, 2026 positive
Earnings Scheduled For May 6, 2026 — benzinga May 6, 2026 neutral
Eyepoint Reported $223M Of Cash And Investments As Of March 31, 2026, With Runway Into Q4 2027 — benzinga May 6, 2026 positive
EyePoint Pharmaceuticals Q1 EPS $(0.99) Misses $(0.80) Estimate, Sales $696.000K Beat $352.833K Estimate — benzinga May 6, 2026 neutral

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards

No bull case signals

Risks

DATA_ISSUE: analyst_target_implausible (raw $37.00 vs price $11.70 — ratio 3.2×). Rejected, falling back to technical TP.

Market cap $0.98B below $1B minimum

Key Metrics

P/E (TTM)—

P/E (Fwd)-4.1

Mkt Cap$981M

EV/EBITDA-3.9

Profit Mgn0.0%

ROE-102.7%

Rev Growth161.7%

Beta1.77

DividendNone

Rating analysts18

Quality Signals

Piotroski F4/9

Options Flow

P/C0.03bullish

IV76%elevated

Max Pain$10-18.7% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

4 floor-breakers·1 ceiling hit

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value5.015%0.75

Quality2.015%0.30

Growth10.015%1.50

Momentum2.010%0.20

Sentiment8.010%0.80

Insider Activity5.010%0.50

Peer Rank3.610%0.36

Technical Setup7.45%0.37

Risk Profile3.45%0.17

Catalyst2.55%0.13

Overall (Σ contributions)5.08

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe

0.0

Roa

0.0

Gross Margin

0.0

Net Margin

0.0

Fcf Quality

0.0

Piotroski F

4.4

Moat

5.0

Current Ratio

6.3

Cash-burning: FCF -2216% of revenueNo competitive moatQuality concerns

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd

0.9

Obv

1.0

Ma Position

2.2

Volume

2.4

Rsi

3.5

Volume distribution (falling OBV)Below 200-MA but MA still rising (+4.3%/30d) — pullback in uptrend, not confirmed weakness

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Earnings History

0.0

Surprise Avg

0.0

Erm

5.0

Earnings Timing

5.0

Earnings concerns: 0B/4M

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank

0.0

Value Rank

5.0

Growth Rank

9.3

Industry growth leader

GatesMomentum 2.0<4.5A.R:R UPSIDE_EXHAUSTED (upside=0.0%)Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 78d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARFalling KnifeSuitability: Aggressive

RSI

32 · Neutral

↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $11.68Resistance $15.18

Price Targets

$11

$15

A.Upside+21.0%

A.R:R0.0:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! DATA_ISSUE: analyst_target_implausible (raw $37.00 vs price $11.70 — ratio 3.2×). Rejected, falling back to technical TP.

! Market cap $0.98B below $1B minimum

! Momentum score 2.0/10 — below 4.5 minimum

Earnings

0/4 beats

Next Earnings2026-08-05 (78d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is EYPT stock a buy right now?

Hold if already holding. Not a fresh buy at $12.30, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $37.00 vs price $11.70 — ratio 3.2×). Rejected, falling back to technical TP.; Market cap $0.98B below $1B minimum. Chart setup: Death cross, below all MAs, RSI 32, MACD bearish. Market cap $0.98B below $1B minimum. Not in investable universe. Target $14.88 (+21.0%), stop $11.33 (−8.6%), A.R:R 0.0:1. Score 5.1/10, moderate confidence.

What is the EYPT stock price target?

Take-profit target: $14.88 (+27.2% upside). Target $14.88 (+21.0%), stop $11.33 (−8.6%), A.R:R 0.0:1. Stop-loss: $11.33.

What are the risks of investing in EYPT?

DATA_ISSUE: analyst_target_implausible (raw $37.00 vs price $11.70 — ratio 3.2×). Rejected, falling back to technical TP.; Market cap $0.98B below $1B minimum.

Is EYPT overvalued or undervalued?

EyePoint, Inc. trades at a P/E of N/A (forward -4.1). TrendMatrix value score: 5.0/10. Verdict: Hold.

What do analysts say about EYPT?

18 analysts cover EYPT with a consensus score of 4.3/5. Average price target: $37.

What does EyePoint, Inc. do?EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious...

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.